Anakinra could represent a promising therapeutic approach in these life-threatening disorders that are likely underdiagnosed and often difficult to treat.

Ferumoxytol was effective in treating IDA in our small study. Slow infusion rate and close monitoring allowed early detection of the infrequent ADRs.

Ferumoxytol doses of up to 12 mg elemental iron/kg administered over 15-60 minutes seem to be well tolerated in pediatric patients. Larger prospective studies are needed to determine the incidence and severity of adverse effects associated with ferumoxytol, both during administration and immediately after. Long-term studies will be required to assess to risk for iron overload toxicity.

OBJECTIVE Preterm infants often require caffeine for the treatment of apnea. While the maintenance dose of caffeine citrate is usually administered once daily per FDA labeling, many providers administer the maintenance dose in two divided doses. This study evaluated the effectiveness of a twice daily dosing regimen of caffeine for apnea of prematurity. METHODS This was a retrospective analysis conducted from 2013–2018 that included preterm infants who received caffeine that was dosed both once and twice daily respectively. The primary outcome of our study was a composite of the number of apneic and bradycardic events for five 24-hour periods prior to switching to twice daily dosing of caffeine and five 24-hour periods after switching to twice daily dosing of caffeine. RESULTS The median five-day average incidence of apnea and bradycardia during the once and twice daily dosing periods was 6.2 events and 6.4 events respectively (p=0.09). CONCLUSIONS There is little benefit of twice daily dosing of caffeine for apnea of prematurity.